In a clinical trial, vaccination of melanoma patients with TAA‐loaded autologous pDCs drove antigen‐specific CD8+ and CD4+ T‐cell responses and improved OS49 showing the reversibility of pDCs subversion by tumor cells. This evidence concerns the gene CD4 and melanoma.